CAMP4 Therapeutics Corporation AI Stock Analysis
Want to see CAMP full AI Analyst Report?
CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis
CAMP4 Therapeutics Corporation
(NASDAQ:CAMP)
The score is primarily held down by weak financial performance (large losses and continued cash burn on a small, declining revenue base), partially offset by a comparatively healthier balance sheet with low leverage. Technicals are mixed with neutral momentum but a weaker longer-term trend, and valuation provides limited support due to a negative P/E and no dividend yield data.
CAMP4 Therapeutics Corporation (CAMP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $257.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 242.41K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 1.78
- Revenue Growth
- 39.93%
- EPS Growth
- 16.95%
- Country
- US
- Employees
- 48
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CAMP4 Therapeutics Corporation Business Overview & Revenue Model
Company Description
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
CAMP4 Therapeutics Corporation Earnings Call Summary
The earnings call presented a mixed picture with strong strategic initiatives, cost reduction measures, and new product launches countered by significant revenue and gross margin declines, as well as a notable goodwill impairment.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the CalAmp Corp. Q3 FY '24 Earnings Call, several key metrics and guidance were discussed. The company reported total revenues of $53.6 million, marking a 32% year-over-year and 13% sequential decline, primarily due to reduced sales to TSP customers. Adjusted EBITDA was $1 million, or 2% of revenues, which was below expectations due to lower revenue and gross margin. Recurring application subscription revenue was $17.8 million, with declines in the connected car U.K. operations offset by growth in the K-12 segment. Gross margin decreased to 33% from the previous quarter’s 36%. The call highlighted a cost-reduction initiative expected to save approximately $16 million annually, reducing the adjusted EBITDA breakeven point to $42 million in quarterly revenue. The strategic financing agreement with Lynrock Lake, involving a $45 million term loan, aims to enhance liquidity and support restructuring efforts. Looking ahead, the company anticipates a slight decrease in consolidated revenues with stable adjusted EBITDA in Q4, expecting industrial market segment revenues to normalize while seeing some recovery in TSP customer orders.
CAMP4 Therapeutics Corporation Financial Statement Overview
Summary
Overall financial profile is weak due to very small and declining TTM revenue ($3.4M, -18.9% growth), very large losses (net loss $121.1M), and ongoing cash burn (TTM operating cash flow -$25.5M; free cash flow -$26.4M). The main offset is a relatively stronger balance sheet with low leverage (debt-to-equity ~0.06) and improved equity versus 2023, but profitability and cash flow remain the dominant constraints.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Nov 2023 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.32M | 3.50M | 652.00K | 350.00K | 294.95M | 295.84M |
| Gross Profit | 4.28M | 1.86M | 652.00K | 350.00K | 109.01M | 121.89M |
| EBITDA | -86.40M | -50.42M | -51.39M | -50.20M | -24.20M | -2.64M |
| Net Income | -121.10M | -80.40M | -51.79M | -49.29M | -32.49M | -27.99M |
Balance Sheet | ||||||
| Total Assets | 134.01M | 117.81M | 78.31M | 54.95M | 102.55M | 402.29M |
| Cash, Cash Equivalents and Short-Term Investments | 124.52M | 109.52M | 64.04M | 38.38M | 83.19M | 91.11M |
| Total Debt | 6.45M | 1.97M | 8.65M | 11.69M | 12.39M | 209.17M |
| Total Liabilities | 26.92M | 70.10M | 15.16M | 178.68M | 180.08M | 322.11M |
| Stockholders Equity | 107.09M | 47.70M | 63.14M | -123.73M | -77.53M | 80.18M |
Cash Flow | ||||||
| Free Cash Flow | -26.41M | -29.83M | -46.00M | -44.83M | -42.57M | -17.52M |
| Operating Cash Flow | -25.54M | -29.55M | -45.56M | -44.16M | -38.54M | -4.22M |
| Investing Cash Flow | -869.00K | -243.00K | -441.00K | -678.00K | -4.03M | -7.58M |
| Financing Cash Flow | 75.67M | 75.89M | 71.66M | 301.00K | 100.16M | -2.64M |
CAMP4 Therapeutics Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 4.10 is above the 20-day moving average (MA) of 3.86, above the 50-day MA of 3.84, and below the 200-day MA of 4.20, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 30.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.
CAMP4 Therapeutics Corporation Risk Analysis
CAMP4 Therapeutics Corporation disclosed 87 risk factors in its most recent earnings report. CAMP4 Therapeutics Corporation reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskCAMP4 Therapeutics Corporation Peers Comparison
Overall Rating
RLMD48Neutral
CAMP47Neutral
BYSI45Neutral
INKT45Neutral
OSTX43Neutral
ARTV40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $304.61M | -3.86 | -37.25% | ― | ― | 58.31% | |
| 47Neutral | $251.02M | -2.00 | -261.83% | ― | 39.93% | 16.95% | |
| 45Neutral | $18.76M | 0.41 | -208.57% | ― | ― | ― | |
| 45Neutral | $47.67M | -3.95 | 107.71% | ― | ― | 25.94% | |
| 43Neutral | $38.95M | -0.83 | 1.47% | ― | ― | -30.21% | |
| 40Underperform | $190.81M | -1.26 | -45.32% | ― | ― | 7.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CAMP | CAMP4 Therapeutics Corporation | 4.10 | 0.59 | 16.81% | |
| RLMD | Relmada Therapeutics Inc | 2.85 | -1.47 | -33.91% | |
| BYSI | Beyondspring | 0.45 | -1.29 | -73.97% | |
| INKT | Mink Therapeutics, Inc. | 8.84 | -2.04 | -18.75% | |
| ARTV | Artiva Biotherapeutics, Inc. | 3.77 | 0.60 | 18.93% | |
| OSTX | OS Therapies Incorporated | 0.92 | -0.70 | -43.27% |
CAMP4 Therapeutics Corporation Corporate Events
CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder
PositiveOn September 28, 2026, CAMP4 Therapeutics held an Analyst Day to detail the design of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder, a randomized, double-blind, placebo-controlled multiple ascending dose study in children...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
